SCHEMBL10305022

SCHEMBL10305022

CCc1nc(-c2ccccc2C)cnc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HEXA P06865 2/20 0.54
HEXB P07686 2/20 0.54
ATR Q13535 5/20 0.50
PRKDC P78527 1/20 0.50
TLR8 Q9NR97 1/20 0.41
IDO1 P14902 1/20 0.39
METAP2 P50579 1/20 0.39
LCK P06239 1/20 0.38
KDR P35968 1/20 0.38
JAK3 P52333 1/20 0.38
MAPK14 Q16539 1/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
HSP90AA1 P07900 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
PIK3CD O00329 1/20 0.37
DPP4 P27487 1/20 0.37
REN P00797 1/20 0.36
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346755 0.85 HEXA (0.46) HEXAHEXBATRPRKDCTLR8
SCHEMBL28174453 0.82 ATR (0.56) HEXAHEXBATRPRKDCTLR8
SCHEMBL13575848 0.80 ATR (0.44) HEXAHEXBATRPRKDCTLR8
SCHEMBL10304952 0.79 ATR (0.48) HEXAHEXBATRPRKDCTLR8
SCHEMBL17204032 0.78 ATR (0.52) HEXAHEXBATRPRKDCTLR8
SCHEMBL10305052 0.75 ATR (0.50) ATRPRKDCIDO1METAP2LCK
SCHEMBL22553122 0.74 ATR (0.49) ATRPRKDCALOX5APFEN1PIK3CD
SCHEMBL11909154 0.73 ATR (0.72) ATRPRKDCLDHALDHB
SCHEMBL3461548 0.73 ATR (0.68) ATRPRKDCLDHALDHB
SCHEMBL22553206 0.72 ATR (0.47) HEXAHEXBATRPRKDCTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
US-8071766-B2 HSP90 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-06 US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 HEXA 3665/4885HEXB 3713/4885ATR 2875/4885
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 HEXA 3665/4885HEXB 3713/4885ATR 2875/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 HEXA 3665/4885HEXB 3713/4885ATR 2875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.